Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes

Sally M Hunter, Michael Stephen Anglesio, Georgina Louise Ryland, Raghwa Sharma, Yoke Eng Chiew, Simone M Rowley, Maria A Doyle, Jason Li, C Blake Gilks, Phillip Moss, Prue E Allan, Andrew Stephens, David G Huntsman, Anna DeFazio, David D L Bowtell, Kylie Louise Gorringe, Ian G Campbell

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Low grade serous ovarian tumours are a rare and under-characterised histological subtype of epithelial ovarian tumours, with little known of the molecular drivers and facilitators of tumorigenesis beyond classic oncogenic RAS/RAF mutations. With a move towards targeted therapies due to the chemoresistant nature of this subtype, it is pertinent to more fully characterise the genetic events driving this tumour type, some of which may influence response to therapy and/or development of drug resistance. We performed genome-wide high-resolution genomic copy number analysis (Affymetrix SNP6.0) and mutation hotspot screening (KRAS, BRAF, NRAS, HRAS, ERBB2 and TP53) to compare a large cohort of ovarian serous borderline tumours (SBTs, n = 57) with low grade serous carcinomas (LGSCs, n = 19). Whole exome sequencing was performed for 13 SBTs, nine LGSCs and one mixed low/high grade carcinoma. Copy number aberrations were detected in 61 (35/57) of SBTs, compared to 100 (19/19) of LGSCs. Oncogenic RAS/RAF/ERBB2 mutations were detected in 82.5 (47/57) of SBTs compared to 63 (12/19) of LGSCs, with NRAS mutations detected only in LGSC. Some copy number aberrations appeared to be enriched in LGSC, most significantly loss of 9p and homozygous deletions of the CDKN2A/2B locus. Exome sequencing identified BRAF, KRAS, NRAS, USP9X and EIF1AX as the most frequently mutated genes. We have identified markers of progression from borderline to LGSC and novel drivers of LGSC. USP9X and EIF1AX have both been linked to regulation of mTOR, suggesting that mTOR inhibitors may be a key companion treatment for targeted therapy trials of MEK and RAF inhibitors.
Original languageEnglish
Pages (from-to)37663 - 37677
Number of pages15
JournalOncotarget
Volume6
Issue number35
DOIs
Publication statusPublished - 2015

Cite this

Hunter, S. M., Anglesio, M. S., Ryland, G. L., Sharma, R., Chiew, Y. E., Rowley, S. M., ... Campbell, I. G. (2015). Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget, 6(35), 37663 - 37677. https://doi.org/10.18632/oncotarget.5438
Hunter, Sally M ; Anglesio, Michael Stephen ; Ryland, Georgina Louise ; Sharma, Raghwa ; Chiew, Yoke Eng ; Rowley, Simone M ; Doyle, Maria A ; Li, Jason ; Gilks, C Blake ; Moss, Phillip ; Allan, Prue E ; Stephens, Andrew ; Huntsman, David G ; DeFazio, Anna ; Bowtell, David D L ; Gorringe, Kylie Louise ; Campbell, Ian G. / Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. In: Oncotarget. 2015 ; Vol. 6, No. 35. pp. 37663 - 37677.
@article{e29504d2f5b94a159344f66e770f6c35,
title = "Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes",
abstract = "Low grade serous ovarian tumours are a rare and under-characterised histological subtype of epithelial ovarian tumours, with little known of the molecular drivers and facilitators of tumorigenesis beyond classic oncogenic RAS/RAF mutations. With a move towards targeted therapies due to the chemoresistant nature of this subtype, it is pertinent to more fully characterise the genetic events driving this tumour type, some of which may influence response to therapy and/or development of drug resistance. We performed genome-wide high-resolution genomic copy number analysis (Affymetrix SNP6.0) and mutation hotspot screening (KRAS, BRAF, NRAS, HRAS, ERBB2 and TP53) to compare a large cohort of ovarian serous borderline tumours (SBTs, n = 57) with low grade serous carcinomas (LGSCs, n = 19). Whole exome sequencing was performed for 13 SBTs, nine LGSCs and one mixed low/high grade carcinoma. Copy number aberrations were detected in 61 (35/57) of SBTs, compared to 100 (19/19) of LGSCs. Oncogenic RAS/RAF/ERBB2 mutations were detected in 82.5 (47/57) of SBTs compared to 63 (12/19) of LGSCs, with NRAS mutations detected only in LGSC. Some copy number aberrations appeared to be enriched in LGSC, most significantly loss of 9p and homozygous deletions of the CDKN2A/2B locus. Exome sequencing identified BRAF, KRAS, NRAS, USP9X and EIF1AX as the most frequently mutated genes. We have identified markers of progression from borderline to LGSC and novel drivers of LGSC. USP9X and EIF1AX have both been linked to regulation of mTOR, suggesting that mTOR inhibitors may be a key companion treatment for targeted therapy trials of MEK and RAF inhibitors.",
author = "Hunter, {Sally M} and Anglesio, {Michael Stephen} and Ryland, {Georgina Louise} and Raghwa Sharma and Chiew, {Yoke Eng} and Rowley, {Simone M} and Doyle, {Maria A} and Jason Li and Gilks, {C Blake} and Phillip Moss and Allan, {Prue E} and Andrew Stephens and Huntsman, {David G} and Anna DeFazio and Bowtell, {David D L} and Gorringe, {Kylie Louise} and Campbell, {Ian G}",
year = "2015",
doi = "10.18632/oncotarget.5438",
language = "English",
volume = "6",
pages = "37663 -- 37677",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "35",

}

Hunter, SM, Anglesio, MS, Ryland, GL, Sharma, R, Chiew, YE, Rowley, SM, Doyle, MA, Li, J, Gilks, CB, Moss, P, Allan, PE, Stephens, A, Huntsman, DG, DeFazio, A, Bowtell, DDL, Gorringe, KL & Campbell, IG 2015, 'Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes' Oncotarget, vol. 6, no. 35, pp. 37663 - 37677. https://doi.org/10.18632/oncotarget.5438

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. / Hunter, Sally M; Anglesio, Michael Stephen; Ryland, Georgina Louise; Sharma, Raghwa; Chiew, Yoke Eng; Rowley, Simone M; Doyle, Maria A; Li, Jason; Gilks, C Blake; Moss, Phillip; Allan, Prue E; Stephens, Andrew; Huntsman, David G; DeFazio, Anna; Bowtell, David D L; Gorringe, Kylie Louise; Campbell, Ian G.

In: Oncotarget, Vol. 6, No. 35, 2015, p. 37663 - 37677.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes

AU - Hunter, Sally M

AU - Anglesio, Michael Stephen

AU - Ryland, Georgina Louise

AU - Sharma, Raghwa

AU - Chiew, Yoke Eng

AU - Rowley, Simone M

AU - Doyle, Maria A

AU - Li, Jason

AU - Gilks, C Blake

AU - Moss, Phillip

AU - Allan, Prue E

AU - Stephens, Andrew

AU - Huntsman, David G

AU - DeFazio, Anna

AU - Bowtell, David D L

AU - Gorringe, Kylie Louise

AU - Campbell, Ian G

PY - 2015

Y1 - 2015

N2 - Low grade serous ovarian tumours are a rare and under-characterised histological subtype of epithelial ovarian tumours, with little known of the molecular drivers and facilitators of tumorigenesis beyond classic oncogenic RAS/RAF mutations. With a move towards targeted therapies due to the chemoresistant nature of this subtype, it is pertinent to more fully characterise the genetic events driving this tumour type, some of which may influence response to therapy and/or development of drug resistance. We performed genome-wide high-resolution genomic copy number analysis (Affymetrix SNP6.0) and mutation hotspot screening (KRAS, BRAF, NRAS, HRAS, ERBB2 and TP53) to compare a large cohort of ovarian serous borderline tumours (SBTs, n = 57) with low grade serous carcinomas (LGSCs, n = 19). Whole exome sequencing was performed for 13 SBTs, nine LGSCs and one mixed low/high grade carcinoma. Copy number aberrations were detected in 61 (35/57) of SBTs, compared to 100 (19/19) of LGSCs. Oncogenic RAS/RAF/ERBB2 mutations were detected in 82.5 (47/57) of SBTs compared to 63 (12/19) of LGSCs, with NRAS mutations detected only in LGSC. Some copy number aberrations appeared to be enriched in LGSC, most significantly loss of 9p and homozygous deletions of the CDKN2A/2B locus. Exome sequencing identified BRAF, KRAS, NRAS, USP9X and EIF1AX as the most frequently mutated genes. We have identified markers of progression from borderline to LGSC and novel drivers of LGSC. USP9X and EIF1AX have both been linked to regulation of mTOR, suggesting that mTOR inhibitors may be a key companion treatment for targeted therapy trials of MEK and RAF inhibitors.

AB - Low grade serous ovarian tumours are a rare and under-characterised histological subtype of epithelial ovarian tumours, with little known of the molecular drivers and facilitators of tumorigenesis beyond classic oncogenic RAS/RAF mutations. With a move towards targeted therapies due to the chemoresistant nature of this subtype, it is pertinent to more fully characterise the genetic events driving this tumour type, some of which may influence response to therapy and/or development of drug resistance. We performed genome-wide high-resolution genomic copy number analysis (Affymetrix SNP6.0) and mutation hotspot screening (KRAS, BRAF, NRAS, HRAS, ERBB2 and TP53) to compare a large cohort of ovarian serous borderline tumours (SBTs, n = 57) with low grade serous carcinomas (LGSCs, n = 19). Whole exome sequencing was performed for 13 SBTs, nine LGSCs and one mixed low/high grade carcinoma. Copy number aberrations were detected in 61 (35/57) of SBTs, compared to 100 (19/19) of LGSCs. Oncogenic RAS/RAF/ERBB2 mutations were detected in 82.5 (47/57) of SBTs compared to 63 (12/19) of LGSCs, with NRAS mutations detected only in LGSC. Some copy number aberrations appeared to be enriched in LGSC, most significantly loss of 9p and homozygous deletions of the CDKN2A/2B locus. Exome sequencing identified BRAF, KRAS, NRAS, USP9X and EIF1AX as the most frequently mutated genes. We have identified markers of progression from borderline to LGSC and novel drivers of LGSC. USP9X and EIF1AX have both been linked to regulation of mTOR, suggesting that mTOR inhibitors may be a key companion treatment for targeted therapy trials of MEK and RAF inhibitors.

UR - http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=5438&pubmed-linkout=1

U2 - 10.18632/oncotarget.5438

DO - 10.18632/oncotarget.5438

M3 - Article

VL - 6

SP - 37663

EP - 37677

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 35

ER -

Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM et al. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget. 2015;6(35):37663 - 37677. https://doi.org/10.18632/oncotarget.5438